T. Rowe Price Associates’s Oruka Therapeutics ORKA Stock Holding History

T. Rowe Price Associates’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$79.8M	Buy	838,603 +111,154	+15%	+$7.41M	0.01%	750
2026 Q1	$35.7M	Buy	727,449 +78,103	+12%	+$2.71M	﹤0.01%	878
2025 Q4	$19.7M	Buy	649,346 +22,540	+4%	+$628K	﹤0.01%	1057
2025 Q3	$12.1M	Buy	626,806 +215,925	+53%	+$3.2M	﹤0.01%	1180
2025 Q2	$4.61M	Sell	410,881 -721	-0.2%	-$7.51K	﹤0.01%	1296
2025 Q1	$4.22M	Sell	411,602 -915,291	-69%	-$11.4M	﹤0.01%	1298
2024 Q4	$25.7M	Buy	1,326,893 +1,047,245	+374%	+$25.5M	﹤0.01%	929
2024 Q3	$6.86M	Buy	+279,648	New	+$9.73M	﹤0.01%	1215

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Associates's ORKA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Oruka Therapeutics (ORKA) stake by 15% in Q2 2026, buying an estimated $7.41M and bringing the position to 838,603 shares worth $79.8M. The position accounts for 0.01% of the portfolio, ranked #750.

T. Rowe Price Associates first reported a position in ORKA in Q3 2024 and has held it in 8 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

T. Rowe Price Associates held 838,603 shares of Oruka Therapeutics worth $79.8M as of Q2 2026.
T. Rowe Price Associates bought 111,154 Oruka Therapeutics shares in Q2 2026, an estimated $7.41M.
Oruka Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #750 holding.
T. Rowe Price Associates first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 8 quarters since.
256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.